主页 > 医学信息 >
【文摘发布】HBsAg蛋白+树突状细胞能对乙肝疫苗
Author: Fazle Akbar SM, Furukawa S, Yoshida O, Hiasa Y, Horiike N, Onji M.
Sourse: J Hepatol. 2007 Apr 9; [Epub ahead of print]
BACKGROUND/AIMS: Antigen-pulsed dendritic cells (DCs) are now used for treatment of patients with cancers, however, the efficacy of these DCs has never been evaluated for prophylactic purposes. The aim of this study was (1) to prepare hepatitis B surface antigen (HBsAg)-pulsed human blood DCs, (2) to assess immunogenicity of HBsAg-pulsed DCs in vitro and (3) to evaluate the efficacy of HBsAg-pulsed DCs in hepatitis B (H vaccine nonresponders. METHODS: Human peripheral blood DCs were cultured with HBsAg to prepare HBsAg-pulsed DCs. The expression of immunogenic epitopes of HBsAg on HBsAg-pulsed DCs was assessed in vitro. Finally, HBsAg-pulsed DCs were administered, intradermally to six HB vaccine nonresponders and the levels of antibody to HBsAg (anti-HBs) in the sera were assessed. RESULTS: HB vaccine nonresponders did not exhibit features of immediate, early or delayed adverse reactions due to administration of HBsAg-pulsed DCs. Anti-HBs were detected in the sera of all HB vaccine nonresponders within 28 days after administration of HBsAg-pulsed DCs. CONCLUSIONS: This study opened a new field of application of antigen-pulsed DCs for prophylactic purposes when adequate levels of protective antibody cannot be induced by traditional vaccination approaches.
PMID: 17467112 本人已认领该文编译，48小时后若未提交译文，请其他战友自由认领 Induction of anti-HBs in HB vaccine nonresponders in vivo by hepatitis B surface antigen-pulsed blood dendritic cells
HBsAg蛋白+树突状细胞能对乙肝疫苗无应答者产生表面抗体
血树突状细胞负载HBsAg能诱导乙肝疫苗无应答者体内产生HBsAb Pulse应该翻译为“冲击”或“负载”，不是“脉冲式”。 Induction of anti-HBs in HB vaccine nonresponders in vivo by hepatitis B surface antigen-pulsed blood dendritic cells.
应该翻译为：HBcAg负载的外周血树突状细胞可以诱导HB疫苗无应答者在体内产生HBsAb
楼上战友翻译的意思已经完全变了样，该文章主要是针对利用抗原负载的DC对HB疫苗无应答者进行刺激，考察HBsAg-DC诱导体内产生抗HBs抗体的能力和效果。所以楼上战友的翻译意思基本上可以认为是对文章内容的误解误译。 背景：抗原负载树突状细胞目前常用于癌症的治疗。然而，目前仍未有关于该类DC在预防性用途上的效能评价。
该研究的目的：（1）制备HBsAg负载的人外周血树状突细胞；（2）评估此类抗原负载的树突状细胞脉在体外的免疫原性；（3）评估HBsAg负载的树突状细胞对乙肝疫苗无应答者的免疫效能。
方法：人外周血树突状细胞的培养加入HBsAg，以制备HBsAg负载的树突状细胞。在体外检测HBsAg负载的树突状细胞的表面免疫原性HBsAg表位的表达情况。最后，6个HB疫苗无应答志愿者接受了皮内注射HBsAg负载的树突状细胞，并在接种后一段时间内检测志愿者体内的血清抗HBs抗体的水平。
结果：乙肝疫苗无应答者接受HBsAg负载的树突状细胞免疫接种后并未发生直接的、早期或者迟发的不良反应。接受该免疫接种后28内，在全部HB疫苗无应答者的血清中均能检测到抗HBs抗体。
结论：当传统HB疫苗无法诱导机体产生足够的保护性抗体时，该方法开创了抗原负载树突状细胞在预防性应用上的新领域。
阅读本文的人还阅读：
作者:admin@医学,生命科学 2010-10-03 17:11
医学,生命科学网